We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
- Authors
Ko, Richard H; Ji, Lingyun; Barnette, Phillip; Bostrom, Bruce; Hutchinson, Raymond; Raetz, Elizabeth; Seibel, Nita L; Twist, Clare J; Eckroth, Elena; Sposto, Richard; Gaynon, Paul S; Loh, Mignon L
- Abstract
Despite improvements in treatment, approximately 20% of patients with acute lymphoblastic leukemia (ALL) experience relapse and do poorly. The Therapeutic Advances in Childhood Leukemia (TACL) Consortium was assembled to assess novel drugs for children with resistant leukemia. We hypothesize that novel agents and combinations that fail to improve baseline complete remission rates in comparable populations are unlikely to contribute to better outcomes and should be abandoned. We sought to define response rates and disease-free survival (DFS) rates in patients treated at TACL institutions, which could serve as a comparator for future studies.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 4, p648
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.22.2950